Glenmark gains on USFDA nod for diarrhoea drug

Shares in Glenmark Pharmaceuticals gain 2.5 percent after US health regulators approved Salix Pharmaceuticals Ltd's drug to treat diarrhoea in HIV/AIDS patients on qantiretroviral therapy, a combination of medicines used to treat HIV infection.

Glenmark will be the active pharmaceutical ingredients supplier for the drug to Salix in regulated markets.

An international arbitrator ruled in August 2012 that Glenmark Pharmaceuticals has the right to sell its HIV-associated diarrhoea drug Crofelemer in 140 countries.

Edelweiss in a report says, "The overall potential market for Crofelemer is anticipated at USD 300 million-USD 500 million and peak potential revenue for Glenmark, from API supply, could be USD 15-20 million per annum."

Anda sedang membaca artikel tentang

Glenmark gains on USFDA nod for diarrhoea drug

Dengan url

https://sehatgayahidup.blogspot.com/2013/01/glenmark-gains-on-usfda-nod-for.html

Anda boleh menyebar luaskannya atau mengcopy paste-nya

Glenmark gains on USFDA nod for diarrhoea drug

namun jangan lupa untuk meletakkan link

Glenmark gains on USFDA nod for diarrhoea drug

sebagai sumbernya